Dark

ATNM
Actinium Pharmaceuticals, Inc
stock NYSEAMERICAN

At Close

Jul 29, 2026 3:44:28 PM EDT

0.8400USD+0.358%(+0.0030)1,316

0.7100Bid 0.9700Ask 0.2600Spread

Pre-market

Jul 31, 2026 8:31:30 AM EDT

0.8810USD+1.667%(+0.8810)1,000

After-hours

Jul 30, 2026 4:25:30 PM EDT

0.8490USD+1.083%(+0.0090)422

OverviewOptionsHistoricalExchangesShortsNews

Jan 5, 2022

07:37AM EST Actinium Pharmaceuticals, Inc. And EpicentRx Announce Research Collaboration To Combine Targeted Radiotherapies With Next Generation CD47/SIRP Immunotherapy Benzinga

07:34AM EST EpicentRx Enters Research Collaboration To Study Actinium's Actimab-A Targeted Radiotherapy In Combination With RRx-001 RTTNews

07:31AM EST Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRP Immunotherapy PR Newswire

Dec 14, 2021

08:38AM EST Actinium Reports Positive Findings From Phase 1 Study Of RTTNews

08:18AM EST Actinium Reports Encouraging Data From Phase 1 Portion Of RTTNews

08:12AM EST Actinium Announces 72% MRD Negativity Rate In Phase 1 Study Of Actimab-A/CLAG-M For Patients With Refractory AML RTTNews

08:05AM EST Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate In The Recently Completed Phase 1 Study Of Actimab-A In Combination With CLAG-M For Patients With Relapsed Or Refractory AML Benzinga

08:01AM EST Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML PR Newswire

07:52AM EST Actinium Reports 2 Remissions&67% ORR In Patients With TP53 Mutation In Phase 1 Portion Of Actimab-A Venetoclax RTTNews

07:49AM EST Actinium Pharmaceuticals Reports 2 Remissions And 67% ORR In Patients With A TP53 Mutation In The Phase 1 Portion Of The Actimab-A Venetoclax Combination Trial In Patients With Relapsed Or Refractory AML At The 63rd ASH Annual Meeting Benzinga

07:45AM EST with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting PR Newswire

Dec 13, 2021

09:08AM EST Actinium Pharma Posts Positive Data From SIERRA Trial For RTTNews

07:38AM EST Actinium Pharma Presents Positive Data From Fully Enrolled Pivotal Phase 3 SIERRA Trial Of Iomab-B RTTNews

07:33AM EST Actinium Pharma Gives an Update at ASH Conference Benzinga

07:31AM EST for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting PR Newswire

Dec 8, 2021

08:26AM EST Actinium Pharmaceuticals, Inc. Announces Participation In Two Panel Discussions At 3rd Targeted Radiopharmaceuticals Summit Dec. 9 Benzinga

08:26AM EST Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions PR Newswire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 12, 2021

08:32AM EST Actinium Presents Data With CD47 Immunotherapy In Combination With HER2-Directed Targeted Radiotherapy In Solid Tumors RTTNews

08:18AM EST Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:15AM EST a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference PR Newswire

08:14AM EST Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting Benzinga

08:02AM EST Actinium Highlights Actimab-A Combined With CD47 Immunotherapy Results RTTNews

08:01AM EST Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference PR Newswire

Nov 4, 2021

09:27AM EDT Actinium Announces Completion Of Enrollment Of Actimab-A CLAG-M Combination Trial In Patients With Relapsed Or Refractory Acute Myeloid Leukemia Fit For Induction Therapy Benzinga

09:07AM EDT Actinium Announces Completion Of Enrollment Of Actimab-A CLAG-M Combination Trial In Refractory Acute Myeloid Leukemia RTTNews

09:06AM EDT Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy PR Newswire

09:05AM EDT Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting PR Newswire

Oct 27, 2021

12:12PM EDT From BZ's Global Small Cap Conference: Actinium Pharmaceuticals CFO Highlights Actimab-A + CLAG-M Combo Phase 1 Results Benzinga

12:03PM EDT From BZ's Global Small Cap Conference: Actinium Pharmaceuticals CFO Says Co Has Only CD45 Targeting Asset In Market Benzinga

12:02PM EDT From BZ's Global Small Cap Conference: Actinium Pharmaceuticals CFO Highlights ARCs Pipeline; Says Clinical Trials Have Made Progress Benzinga

12:00PM EDT From BZ's Global Small Cap Conference: Actinium Pharmaceuticals CFO Steve O'Loughlin Begins Presentation Benzinga

Oct 1, 2021

09:04AM EDT Actinium :Two Abstracts Highlights Combinations Of CD47 With Targeted Radiotherapies In Solid Tumors And Blood Cancers RTTNews

09:02AM EDT Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference PR Newswire

Sep 30, 2021

10:52AM EDT From BZ's Small Cap Healthcare Conference: Actinium Pharmaceuticals, Inc CFO, Steve O'Loughlin Begins Speaking Benzinga

Sep 28, 2021

08:18AM EDT Actinium To Present Ate Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th Benzinga

08:01AM EDT Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare PR Newswire

Sep 27, 2021

08:07AM EDT Actinium Announces Expansion Of R&D Team And Facilities Benzinga

08:02AM EDT Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates PR Newswire

Sep 23, 2021

09:09AM EDT Actinium Promotes Avinash Desai To Chief Medical Officer RTTNews

09:06AM EDT Actinium Appoints Avinash Desai As CMO Benzinga

09:03AM EDT Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel PR Newswire

Sep 20, 2021

08:37AM EDT Actinium to Present at Four Upcoming Investor Conferences PR Newswire

Sep 15, 2021

07:05AM EDT Actinium Completes Enrollment In Pivotal Phase 3 SIERRA Trial Of Iomab-B; Expects Data Updates In Q4 RTTNews

07:02AM EDT Actinium Completes Enrollment In The Pivotal Phase 3 SIERRA Trial Of Iomab-B Benzinga

Aug 17, 2021

01:47PM EDT Mid-Day Market Update: monday.com Jumps Following Strong Q2 Results; Kubient Shares Plunge Benzinga

Aug 3, 2021

06:27AM EDT HC Wainwright & Co. Maintains Buy on Actinium Pharmaceuticals, Lowers Price Target to $45 Benzinga

Jun 28, 2021

08:31AM EDT Actinium Pharmaceuticals Announces Inclusion in Russell Microcap(r) Index PR Newswire

Jun 17, 2021

08:35AM EDT Actinium Announces Patent Covering 'Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate' In EU And japan Benzinga

08:31AM EDT the Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate in the EU and Japan PR Newswire

Jun 15, 2021

02:27PM EDT Actinium's Targeted Radiotherapy Achieves 100% Bone Marrow Transplant Engraftment Benzinga

09:21AM EDT Actinium Pharmaceuticals Inc. (ATNM) said that pivotal phase 3 SIERRA trial data showed 100% bone marrow transplant engraftment in patients treated with Iomab-B. RTTNews

09:04AM EDT Actinium :Phase 3 SIERRA Trial Data Shows 100% Bone Marrow Transplant Engraftment In Patients Treated With Iomab-B RTTNews

09:04AM EDT Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference PR Newswire

08:47AM EDT Actinium Announces Highlighted Safety Data From Its Ongoing Pivotal Phase 3 SIERRA Trial RTTNews

08:46AM EDT Actinium Pharmaceuticals Says Safety Data Highlighting Low Rates Of Adverse Events And Non-Relapse Transplant Related Mortality In Patients Receiving Lomab-B Presented At 2021 SNMMI Virtual Conference Benzinga

Jun 3, 2021

01:08PM EDT Actinium Pharmaceuticals Details SIERRA at Benzinga Global Small Cap Business Conference Benzinga

10:05AM EDT Actinium Activates Radiation Inside the Body for Target Conditioning of Cancer Cells Benzinga

09:43AM EDT Actinium Announces Several Presentations From The Phase 3 SIERRA Study Of Iomab-B RTTNews

09:07AM EDT Actinium Announces Several Presentations from the Phase 3 SIERRA Study of PR Newswire

May 13, 2021

05:13PM EDT Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals Benzinga

01:03PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Says Multiple Clinical And Corporate Milestones Expected Throughout 2021 Enabled By Strong Balance Sheet, Enhanced Clinical Development And R&D Capabilities Benzinga

12:59PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Says Venetoclax Is Used Widely Across AML Segments, However, Most Patients Ultimately Relapse; Preclinical Data Support Mechanistic Synergy Of Actimab-A With Venetoclax Benzinga

12:54PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Says Iomab-ACT Enables Targeted Depletion Of Multiple Immune Cells Implicated In CAR-T Toxicities Benzinga

12:51PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Says SIERRA Trial Is 75% Enrolled; Aims To Complete Enrollment This Year To Present Topline Data On Primary Endpoint 6 Months After Completion Benzinga

12:45PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Says Conditioning Is Needed To Deplete Stem Cells In The Bone Marrow To Facilitate Engraftment Of New Cells Benzinga

12:43PM EDT From BZ Small Cap Event: Actinium Pharma CFO Steve O'Loughlin Now Speaking Live Benzinga

Apr 6, 2021

09:07AM EDT Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly Benzinga

Apr 1, 2021

06:44AM EDT HC Wainwright & Co. Maintains Buy on Actinium Pharmaceuticals, Lowers Price Target to $57 Benzinga

Mar 31, 2021

06:12PM EDT Actinium to Participate in the Cell & Gene Meeting on the Mediterranean PR Newswire

Mar 25, 2021

02:32PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Co Has Over 140 Patents Benzinga

02:31PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Co 'Already Has Strong Inroads' To Clinics Providing Targeted Radiotherapy Benzinga

02:30PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Sees Completing Phase 3 SIERRA Trial In 2021 Benzinga

02:29PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Highlights Actimab-A And Venetoclax Combination Trial Benzinga

02:28PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Looking To Advance Several Trials On Actimab-A; Highlights Phase 1 Results Benzinga

02:25PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Reports 100% Engraftment For All Patients Receiving Therapeutic Dose Of Iomab-B Benzinga

02:22PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Conditioning Matters Because They Are 'Potentially Curative' Benzinga

02:21PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Co Has Initiated Enrollment In Actimab A CD33 Benzinga

02:20PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Co Delivers Radiation From Within The Body Benzinga

02:20PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Says Radiation Is Used To Treat Over 50% Of Cancer Patients Benzinga

02:19PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Highlights AWE Technology Platform, Partnerships Benzinga

02:19PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Highlights 75% Enrollment In Pivotal Phase 3 SIERRA Trial; Says Complete Enrollment Expected Later In 2021 Benzinga

02:17PM EDT From BZ Biotech Conference: Actinium Pharmaceuticals CEO Steve O'Loughlin Begins Presentation Benzinga

09:01AM EDT Actinium Completes Enrollment Of Second Dose Cohort In Actimab-A Venetoclax Combination Trial RTTNews

09:01AM EDT Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A PR Newswire

09:01AM EDT Actinium Announces Completion Of Enrollment Of Second Dose Cohort In Actimab-A Venetoclax Combination Trial For Patients With R/R AML Benzinga

Mar 24, 2021

08:04AM EDT Anthem, Inc. To Acquire Home Health Benefits Manager myNEXUS; Financial Terms Not Disclosed Benzinga

07:32AM EDT Actinium Initiates Patient Enrollment In Iomab-ACT Trial For Targeted Conditioning Prior To CD19 CAR T-Cell Therapy RTTNews

07:32AM EDT Actinium Announces Initiation Of Patient Enrollment In Iomab-ACT Trial For Targeted Conditioning Prior To CD19 CAR T-Cell Therapy Benzinga

07:31AM EDT Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for PR Newswire

Mar 11, 2021

07:04AM EST Actinium To Present On Expansion Af Targeted Conditioning Portfolio At AACR Meeting Apr. 10 Benzinga

07:01AM EST Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with PR Newswire

Mar 3, 2021

07:02AM EST Actinium Appoints Mark Kubik As Chief Business Officer RTTNews

07:02AM EST Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer PR Newswire

Mar 2, 2021

07:31AM EST Actinium Announces Participation in H.C. Wainwright Global Life Sciences PR Newswire

Feb 11, 2021

07:20AM EST Actinium Showcases Conditioning Program With 2 Oral Presentations Highlighting Iomab-B And Pivotal Phase 3 SIERRA Trial RTTNews

07:15AM EST Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting PR Newswire

Feb 10, 2021

07:15AM EST Actinium Announces Participation in BIO CEO & Investor Digital Conference PR Newswire

Jan 20, 2021

07:00AM EST Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor PR Newswire

Jan 13, 2021

07:16AM EST Actinium Pharma Announces Research Collaboration With RTTNews

07:12AM EST Actinium Pharma Reports Research Collaboration With Astellas Pharma To Develop Novel Targeted Radiotherapies Using Its Antibody Warhead Enabling Technology Platform, No Terms Disclosed Benzinga

07:02AM EST Actinium Announces Research Collaboration With Astellas Pharma RTTNews

07:01AM EST Actinium and Astellas Announce Research Collaboration Focused on Novel PR Newswire

Dec 29, 2020

08:51AM EST Actinium Pharmaceuticals, Inc. (ATNM) said Tuesday that the independent Data Monitoring Committee or DMC has completed the single ad hoc interim analysis of the pivotal Phase 3 SIERRA study of Iomab-B for bone marrow transplant (BMT) conditioning in patients aged above 55 with active relapsed or refractory Acute Myeloid Leukemia (R/R AML). RTTNews

08:31AM EST Actinium Reports Successful Pre-Planned Ad Hoc Interim Analysis Of Phase 3 SIERRA Trial RTTNews

08:31AM EST Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 PR Newswire

08:30AM EST Actinium Reports Successful Pre-Planned Ad Hoc Interim Analysis Of Phase 3 SIERRA Trial Benzinga

Dec 9, 2020

08:55AM EST From BZ Small Cap Event: Actinium Pharmaceuticals Says SIERRA Trial Has Demonstrated All Patients Receiving Therapeutic Dose Of Iomab-B Have Been Able To Go On to Bone Marrow Transplant Benzinga

08:55AM EST From BZ Small Cap Event: Actinium Pharmaceuticals Says Estimates ~176K Patients/Year Diagnosed With Blood Cancers Treatable With Bone Marrow Transplant But Only 23K Transplants Performed In 2018, Says Looking To Address Access Gap With Iomab-B Benzinga

08:54AM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Notes Co.'s ARCs Enable Targeted Radiotherapy Directly To Cancer Cells; Says Has Over 130 Patents That Protect Candidates Through 2037 And Beyond Benzinga

08:53AM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Highlights Co. Balance Sheet; ~$48M In Cash, Which Can Fund Operations Through 2021 Benzinga

08:53AM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Says Co. Led By Iomab-B, Which Is In Phase 3 SIERRA Trial; Has Also Expanded Into Bone Marrow, Transplant CAR-T And Gene Therapy Benzinga

08:01AM EST Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit PR Newswire

Dec 8, 2020

01:34PM EST From BZ Small Cap Event: Actinium Pharmaceuticals Says SIERRA Trial Has Demonstrated All Patients Receiving Therapeutic Dose Of Iomab-B Have Been Able To Go On to Bone Marrow Transplant Benzinga

01:32PM EST From BZ Small Cap Event: Actinium Pharmaceuticals Says Estimates ~176K Patients/Year Diagnosed With Blood Cancers Treatable With Bone Marrow Transplant But Only 23K Transplants Performed In 2018, Says Looking To Address Access Gap With Iomab-B Benzinga

01:28PM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Notes Co.'s ARCs Enable Targeted Radiotherapy Directly To Cancer Cells; Says Has Over 130 Patents That Protect Candidates Through 2037 And Beyond Benzinga

01:26PM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Highlights Co. Balance Sheet; ~$48M In Cash, Which Can Fund Operations Through 2021 Benzinga

01:25PM EST From BZ Small Cap Event: Actinium Pharmaceuticals CFO Steve O'Loughlin Says Co. Led By Iomab-B, Which Is In Phase 3 SIERRA Trial; Has Also Expanded Into Bone Marrow, Transplant CAR-T And Gene Therapy Benzinga

09:13AM EST Actinium Pharmaceuticals, Inc. (ATNM) on Tuesday announced that first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in patients with relapsed or refractory Acute Myeloid Leukemia or AML. RTTNews

08:10AM EST Actinium Reveals Promising Data In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML RTTNews

08:03AM EST Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A PR Newswire

08:03AM EST Actinium Reports 67% Overall Response Rate In First Cohort In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML At ASH 2020 Benzinga

Dec 7, 2020

05:22PM EST Schedule Of NYSE-, Nasdaq-Listed Publicly-Traded Companies Presenting At Benzinga's Small Cap Conference Dec. 8-9 Benzinga

08:36AM EST Actinium Presents Interim Data From Pivotal Phase 3 Trial In Patients With R/R AML RTTNews

08:36AM EST Actinium Announces Positive Interim Results From Iomab-B Pivotal Phase 3 SIERRA Trial At 75% Of Total Patient Enrollment At 62nd American Society Of Hematology Annual Meeting Benzinga

08:31AM EST Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting PR Newswire

08:31AM EST Actinium Highlights Iomab-B Safety Data Presented At 62nd Annual American Society Of Hematology Annual Meeting Benzinga

08:19AM EST Actinium Presents Ongoing Pivotal Phase 3 SIERRA Trial Of Iomab-B In Patients With R/R AML RTTNews

08:15AM EST Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society PR Newswire

07:06AM EST Actinium Presents Interim Data From Actimab-A CLAG-M Phase 1 Combination Trial At ASH RTTNews

07:03AM EST Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting Benzinga

07:01AM EST Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial PR Newswire

Dec 3, 2020

07:02AM EST Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American PR Newswire

Dec 1, 2020

07:02AM EST Actinium Appoints Mary Mei Chen As VP Of Clinical Development RTTNews

07:01AM EST Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical PR Newswire

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 23, 2020

07:57AM EST Actinium Pharmaceuticals Inc. (ATNM) highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate or ARC. It comprised of apamistamab and the radioisotope iodine-131 used in the company's lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs. RTTNews

07:06AM EST Actinium Highlights Foundational Patents Covering Composition Of Apamistamab And Iomab-B And Recent EU Patent Activity RTTNews

07:01AM EST Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity PR Newswire

Nov 19, 2020

07:31AM EST Actinium Appoints Avinash Desai EVP Of Clinical Development, Operations And Medical Affairs RTTNews

07:31AM EST Executive Vice President of Clinical Development, Operations and Medical Affairs PR Newswire

Nov 16, 2020

07:01AM EST Actinium to Participate in the Alliance Global Partners' Virtual Healthcare PR Newswire

Nov 11, 2020

08:02AM EST Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination PR Newswire

Nov 4, 2020

12:24PM EST Actinium Pharma Reports 100% Of Evaluable Patients In Third, Planned Final Dose Cohort Of Actimab-A CLAG-M Phase 1 Trial Being Conducted At Medical College Of Wisconsin Achieved Remission Benzinga

12:22PM EST 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 PR Newswire

12:14PM EST Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting PR Newswire

12:03PM EST Actinium Pharma Highlights Poster Presentation At American Society Of Hematology Accepted For Actimab-A Venetoclax Data Benzinga

12:01PM EST Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster PR Newswire

Oct 28, 2020

09:25AM EDT Actinium Pharmaceuticals Inc. (ATNM) said that it has made material advances in its key clinical trials and programs for targeted conditioning and therapeutic combinations this year and anticipate several important milestones before year-end and in 2021. RTTNews

07:18AM EDT UPDATE: Actinium Reports Cash Balance Of $48.2M As Of Sept. 30, 2020 Benzinga

07:17AM EDT Actinium Pharma Gives Corporate Update Covering Progress Made In 2020 Benzinga

07:10AM EDT Actinium Pharma Sees Multiple Milestones In Q4 From ARC Pipeline Incl Phase 3 Data From Pivotal SIERRA Trial RTTNews

07:01AM EDT Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 PR Newswire

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

07:15AM EDT Actinium Pharma Awarded Grant To Study Novel Iomab-ACT Targeted Conditioning With A CD19 CAR T-Cell Therapy RTTNews

07:11AM EDT Actinium Pharma Wins Grant By National Institutes Of Health To Study Novel Iomab-ACT Targeted Conditioning With CD19 CAR T-Cell Therapy, No Terms Disclosed Benzinga

07:01AM EDT Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health PR Newswire

Oct 14, 2020

07:06AM EDT Actinium Pharmaceuticals Announces The Launch Of New Research & Development Lab Facility In New York Benzinga

07:02AM EDT Actinium Pharma Unveils Launch Of Its New R&D Lab Facility In New York City RTTNews

07:01AM EDT Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform PR Newswire

Oct 6, 2020

07:15AM EDT Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion In Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial Benzinga

07:04AM EDT Actinium Pharma Announces Clinical Trial Site Expansion In Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial RTTNews

07:01AM EDT Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its PR Newswire

Sep 23, 2020

07:07AM EDT Actinium Pharmaceuticals Completes First Dosing Cohort In Phase 1 Study Of Actimab-A And Venetoclax Combination Therapy In Relapsed/Refractory AML Patients Benzinga

07:02AM EDT Actinium Pharma Completes First Dosing Cohort In Phase 1 Study Of Actimab-A And Venetoclax Combination Therapy RTTNews

07:01AM EDT Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients PR Newswire

Sep 14, 2020

08:08AM EDT Actinium Pharmaceuticals, Inc. (ATNM) on Monday provided an update on the Actimab-A CLAG-M combination Phase 1 trial being conducted at the Medical College of Wisconsin or MCW, in patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia (AML) age 18 and above, who are fit for intensive therapy. RTTNews

07:07AM EDT Actinium Pharmaceuticals Announces Completion Of Planned Phase 1 Actimab-A CLAG-M Combination Trial In Patients With Relapsed/Refractory AML At Medical College Of Wisconsin Benzinga

07:03AM EDT Actinium Pharma Provides Update On Actimab-A CLAG-M Combination Phase 1 Trial RTTNews

07:01AM EDT Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin PR Newswire

Aug 10, 2020

02:47PM EDT Actinium Pharma Announces Reverse 1-for-30 Stock Split RTTNews

02:31PM EDT Actinium Pharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split Benzinga

02:30PM EDT Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split PR Newswire

Aug 7, 2020

04:05PM EDT Actinium Pharma S-3 Shows Registration For $500M Mixed Securities Offering Benzinga

Aug 6, 2020

09:53AM EDT Actinium 8-K From Wed. Evening Shows Co. Received NYSE American Deficiency Letter Apr. 29, 2020 Related To Non Compliance Of $1 Minimum Last Trade Rule; Notes Oct. 18, 2019 Approval Of 1-For-75 Reverse Split, Has Moved Up Effective Date To Mid Aug. Benzinga